Shanghai Junshi Biosciences Co., Ltd.
Shanghai Junshi Biosciences Co., Ltd. (HKSE: 1877) is trading at HK$18.31, about ₹224 at today's HKD/INR rate, as of 25 Sep 2026, 4:08 AM ET, up 0.44% today. Indian residents can buy Shanghai Junshi Biosciences from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$17.66
Today's high
HK$18.31
52 week low
HK$15.25
52 week high
HK$32.62
1877 opened at HK$18.02, closed previously at HK$18.23, and has traded between HK$15.25 and HK$32.62 over the past 52 weeks.
About
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical firm focused on the research, creation, and marketing of diverse pharmaceutical products. Operating within the People's Republic of China, its therapeutic focus spans oncology, metabolic disorders, autoimmune conditions, neurological ailments, and infectious diseases. Among its offerings is JS001, marketed as TUOYI, a recombinant humanized anti-PD-1 monoclonal antibody. This treatment is prescribed for a wide array of cancers, including melanoma (both cutaneous and mucosal), soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. The company's development pipeline also includes UBP1211, a biosimilar version of Humira, intended for rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Additionally, they are advancing JS002, a recombinant humanized anti-PCSK9 monoclonal antibody designed to address hyperlipidemia, and UBP1213, an injectable recombinant humanized anti-BLyS monoclonal antibody. Further projects encompass JS501, a biosimilar of Avastin; JS003, an injectable recombinant humanized anti-PD-L1 monoclonal antibody; JS101, which acts as a pan-CDK inhibitor; TAB004/JS004, an injectable recombinant humanized anti-BTLA monoclonal antibody; and JS005, another injectable recombinant humanized anti-IL-17A monoclonal antibody. Furthermore, Junshi Biosciences holds partnerships, including an agreement with Eli Lilly and Company to collaboratively develop therapeutic antibodies aimed at the prevention and treatment of COVID-19, the illness resulting from the SARS-CoV-2 novel coronavirus. Another collaboration is with Coherus Biosciences, Inc. for the advancement and commercialization of toripalimab, which is Junshi Biosciences' anti-PD-1 antibody. Established in 2012, Shanghai Junshi Biosciences Co., Ltd. maintains its primary offices in Shanghai, People's Republic of China.
Key statistics
Avg. volume
3.42M
Market cap
HK$25.79B
P/E Ratio
-81.34
Price-to-sales ratio
11.74
Enterprise value
CN¥38.70B
Free cash flow yield
-2.83%
Debt-to-equity ratio
0.99
Return on equity
-7.32%
ROIC
-5.29%
Beta
0.58
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥2.43B
Earnings per share
-CN¥0.84
Free cash flow
-CN¥1.21B
Net profit margin
-14.57%
Gross margin
79.86%
EBITDA
-CN¥599.38M
Revenue growth
24.92%
Similar securities
This is not an investment recommendation
How to buy Shanghai Junshi Biosciences from India
Indian residents can buy Shanghai Junshi Biosciences shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for Shanghai Junshi Biosciences and place an order
Find Shanghai Junshi Biosciences by name or by its ticker, 1877, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Shanghai Junshi Biosciences trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Shanghai Junshi Biosciences position in HKD and INR. Shanghai Junshi Biosciences pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Shanghai Junshi Biosciences from India
Trading and taxes when buying Shanghai Junshi Biosciences from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneShanghai Junshi Biosciences does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Shanghai Junshi Biosciences stock?
Yes. Shanghai Junshi Biosciences (1877) has been listed on the Hong Kong Stock Exchange since 2018, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Shanghai Junshi Biosciences share cost in rupees?
One Shanghai Junshi Biosciences share is HK$18.31 — about ₹224 at an HKD/INR rate of 12.23 on 26 Sep 2026. Both the Shanghai Junshi Biosciences price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Shanghai Junshi Biosciences from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Shanghai Junshi Biosciences?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on Shanghai Junshi Biosciences shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Shanghai Junshi Biosciences price. Paasa issues a capital-gains statement for your return.
Does Shanghai Junshi Biosciences pay a dividend?
No. Shanghai Junshi Biosciences does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Shanghai Junshi Biosciences from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is Shanghai Junshi Biosciences a Hong Kong SAR China company, and does that change how it is taxed?
Shanghai Junshi Biosciences trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Shanghai Junshi Biosciences trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Shanghai Junshi Biosciences shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Shanghai Junshi Biosciences holding, its cost and its closing value.
How do I sell Shanghai Junshi Biosciences and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.